Cataract Clinical Trial
Official title:
CSP #338 - Comparison of Anterior and Posterior Chamber Lens Implants After Vitreous Loss in Attempted Extracapsular Cataract Extraction
| Verified date | October 2015 |
| Source | VA Office of Research and Development |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Federal Government |
| Study type | Interventional |
Objective: The standard definition of failure in cataract surgery is best corrected visual
acuity of less than 20/40 at one year. The specific aim of this cooperative study was to
compare the failure rate for those patients with vitreous loss in whom an PC IOL is placed
to the failure rate for those in whom an AC IOL is placed after vitreous loss.
Design: A total of 437 patients in 15 centers were randomized to AC or PC IOL over a
45-month period and were followed for a minimum of one year. The null hypothesis is that the
rate of failure is the same in the two groups.
All patients who were about to undergo cataract surgery in the participating centers and who
did not meet an exclusion criterion were eligible for the study. At the time of surgery, if
there was vitreous loss, and if in the opinion of the surgeon there was sufficient capsular
support for a posterior chamber lens to be placed, then the patient was randomized into one
of either the anterior or posterior chamber lens groups. The patients were then followed for
complications (e.g., retinal detachment, cystoid macular edema, uveitis, glaucoma, hyphema)
and for the primary end point of visual acuity of 20/40 or better at one postoperative year.
An "Index Group" of about 500 patients without vitreous loss also were followed according to
study protocol. These patients were compared to those in the PC and AC IOL groups with
respect to outcome and baseline characteristics in order to assess the effect of vitreous
loss on complication rates.
All patients were followed at annual intervals until the termination of the study. This
allowed the study to obtain long-term information with regard to visual acuity and
complication rates.
| Status | Completed |
| Enrollment | 1202 |
| Est. completion date | February 1998 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - The principal eligibility criterion was a visually significant lens opacity resulting in a best-corrected distance visual acuity of 20/50 or worse. Exclusion Criteria: - Age less than 18 years - Unwillingness to give informed consent - Unwillingness to agree to protocol follow-up - Visual acuity better than 20/50 - Any other ocular disease which would preclude a final postoperative visual acuity of 20/40 or better (e.g., proliferative diabetic retinopathy, flaucoma, or Fuchs' dystrophy) - History of uveitis - Other contraindication to an IOL - Cataract attributable to trauma - Patient only had one eye with potential for useful vision - Any retinal thickening or definite hard exudates within one disk diameter of center of macula - Patient's other eye already entered into the study. Patients could be screened for the study twice; once for each eye if they had a cataract in both. However, if the first procedure resulted in the patient being entered into the randomized study, the 5% NVP group, or the ICS group, then the second eye was not eligible for the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| VA Office of Research and Development |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
| Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
| Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
| Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
| Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
| Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
| Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
| Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
| Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
| Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
| Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
| Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
| Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
| Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
| Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
| Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
| Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
| Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |